Posttranslational modifications and secretion efficiency of immunogenic hepatitis B virus L protein deletion variants

Virol J. 2013 Feb 25:10:63. doi: 10.1186/1743-422X-10-63.

Abstract

Background: Subviral particles of hepatitis B virus (HBV) composed of L protein deletion variants with the 48 N-terminal amino acids of preS joined to the N-terminus of S protein (1-48preS/S) induced broadly neutralizing antibodies after immunization of mice with a Semliki Forest virus vector. A practical limitation for use as vaccine is the suboptimal secretion of such particles. The role of the N-terminal preS myristoylation in the cellular retention of full-length L protein is described controversially in the literature and the relation of these data to the truncated L protein was unknown. Thus, we studied the effect of preS myristoylation signal suppression on 1-48preS/S secretion efficiency, glycosylation and subcellular distribution.

Findings: The findings are that 1-48preS/S is secreted, and that removal of the N-terminal myristoylation signal in its G2A variant reduced secretion slightly, but significantly. The glycosylation pattern of 1-48preS/S was not affected by the removal of the myristoylation signal (G2A mutant) but was different than natural L protein, whereby N4 of the preS and N3 of the S domain were ectopically glycosylated. This suggested cotranslational translocation of 1-48preS in contrast to natural L protein. The 1-48preS/S bearing a myristoylation signal was localized in a compact, perinuclear pattern with strong colocalization of preS and S epitopes, while the non-myristoylated mutants demonstrated a dispersed, granular cytoplasmic distribution with weaker colocalization.

Conclusions: The large deletion in 1-48preS/S in presence of the myristoylation site facilitated formation and secretion of protein particles with neutralizing preS1 epitopes at their surface and could be a useful feature for future hepatitis B vaccines.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Neutralizing / blood
  • Antigens, Viral / genetics
  • Antigens, Viral / immunology*
  • Antigens, Viral / metabolism
  • Gene Deletion*
  • Genetic Vectors
  • Hepatitis B Antibodies / blood
  • Hepatitis B Vaccines / administration & dosage
  • Hepatitis B Vaccines / genetics
  • Hepatitis B Vaccines / immunology*
  • Hepatitis B virus / genetics
  • Hepatitis B virus / immunology*
  • Mice
  • Neutralization Tests
  • Protein Processing, Post-Translational*
  • Semliki forest virus / genetics
  • Viral Envelope Proteins / genetics*

Substances

  • Antibodies, Neutralizing
  • Antigens, Viral
  • Hepatitis B Antibodies
  • Hepatitis B Vaccines
  • L protein, hepatitis B virus
  • Viral Envelope Proteins